articleMMWR Morbidity and Mortality Weekly ReportMar 7, 2024DIAMOND OA

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024

PubMed
Indexed incrossrefpubmed

Abstract

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for infants aged

Citation impact

198
total citations
FWCI
69.64
Percentile
100%
References
9
Citations per year

Authors

46

Topics & keywords

Keywords
  • Medicine
  • Pediatrics
  • Lower respiratory tract infection
  • Respiratory tract infections
  • Vaccination
  • Immunization
  • Respiratory system
  • Pneumovirinae
No related works found for this paper.

Funding